Innate: Company Presentation (Innate Pharma) - Aug 29, 2015 - "Phase I dose-escalation of IPH201 in combination with lenalidomide (LEN) in 15 patients with relapsed/refractory MM"; "Prior therapies: one prior line: 10 pts; 2 prior lines: 5 pts; prior LEN: 10 pts"; "Treatment: 4 cycles of IPH2101 and LEN; 5 pts received 4 additional cycles; No use of corticosteroids"; "Results: Combination generally well tolerated; IPH2101 PK and PD not affected by co-administration of LEN; Objective responses observed in 33.3% of patients with and without prior LEN exposure, Median PFS of 24 months"
P1 data • Multiple Myeloma • Oncology
|